Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaRecombinant L-asparaginase 1 from Saccharomyces cerevisiae: an allosteric enzyme with antineoplastic activityRecent new drug approvals. Part 1: drugs with pediatric indicationsHLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginaseRationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivationGCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.High-throughput asparaginase activity assay in serum of children with leukemiaL-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of OdishaEarly diagnosis of asparaginase-associated pancreatitis based on elevated serum elastase-1 levels: Case reportsPrevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Dermatologic manifestations of cytotoxic therapy.Asparaginase-associated pancreatitis in children.Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.A critical review on properties and applications of microbial l-asparaginases.Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.Asparaginase pharmacology: challenges still to be faced.Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case reportSevere pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.Reactions related to asparaginase infusion in a 10-year retrospective cohort.Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study.Relationship between modified CT severity index and clinical features of L-asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia.
P2860
Q26738640-4DE3F760-1E50-4AF4-A2EB-E4ACEBF11872Q27026952-CAD0D528-3413-4E96-B333-BC80F823BB1CQ28114319-5E34C817-3516-45A5-ACEE-21677FA93A7BQ28709081-FB4A0874-E66C-4DE5-8EE3-FCBF1F7B33E1Q30371340-555A7558-C896-4E4C-BD61-564CEC4AFCDFQ30457370-FEB02948-BBC2-416C-93E5-FBAC3463F9DAQ34064049-39D582A4-9ECE-44CD-9A1F-9238FF6A2E06Q34325815-4AE49F25-7DA9-4E32-8FC8-03860BA557E7Q34568337-4BD2F4C0-D08D-4C6C-9703-32A528C3A1C6Q35086484-BA1721E0-627A-4581-83B8-0C4854816A8DQ36463010-90457EC0-948C-4A55-9B9B-01418AD98A3CQ36762608-34BF18BC-728E-4A0F-963C-C1A5F22B345FQ37063860-E0E147D7-B858-4935-879B-4BEF7C888BDCQ37311985-121E54FD-703B-448C-A172-11464D741AA4Q37565421-8A21A490-C502-45BD-AC97-60D6359909A0Q37914185-79F853AD-5716-4407-BD25-AE79F19563C0Q37930714-ABA68E57-46F3-405F-B643-EEF5CB112F56Q38036389-6BE6BF88-ADFC-49CC-A675-EBC6EB92347AQ38248280-CE4BF6A9-B7D8-41F7-A69B-F2766F4F394AQ38417141-E906E678-F751-48DF-B182-AC13CE131001Q38696311-C05411BD-F360-4E2E-A339-80EC51136530Q38933372-CB79DFF4-9025-4736-8D7F-42569B38CBADQ38941947-E2985A5B-DAB6-4BA1-897C-AA0083B87C61Q39135887-2D028221-0964-403F-8BA7-8A7ECEC0FBF0Q40243523-4A942DBE-D286-4AAB-ADD6-5CA5DD70C045Q41295156-89D0FB44-717F-4735-AB58-F7EFC35FC8D4Q41960423-AD7E01B4-C83F-4E7F-955C-881C788FE105Q45072276-29C0D1E1-94E3-4B6E-8E24-46CBED9ED659Q45261834-048BFB45-E09D-41F5-A704-5185F1E9DCA8Q45994014-C899FF7E-B93E-4DE1-9454-984817FCE84FQ47133515-B0DBC7F9-CA9A-4E3B-BEF6-D866DBE7C69EQ48262886-151D5809-A598-430B-9FEA-56D6676313F4Q53062852-C4FB3D05-997D-4196-9653-4F4148087863
P2860
Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tolerability and efficacy of L ...... acute lymphoblastic leukemia.
@en
Tolerability and efficacy of L ...... acute lymphoblastic leukemia.
@nl
type
label
Tolerability and efficacy of L ...... acute lymphoblastic leukemia.
@en
Tolerability and efficacy of L ...... acute lymphoblastic leukemia.
@nl
prefLabel
Tolerability and efficacy of L ...... acute lymphoblastic leukemia.
@en
Tolerability and efficacy of L ...... acute lymphoblastic leukemia.
@nl
P1476
Tolerability and efficacy of L ...... acute lymphoblastic leukemia.
@en
P2093
Elizabeth A Raetz
Wanda L Salzer
P304
P356
10.1097/MPH.0B013E3181E6F003
P577
2010-10-01T00:00:00Z